Figure 1. HLA class I status is not associated with pathological response and survival after neoadjuvant treatment. (A) Number of patients with HLA-proficient (n=11) or deficient (n=10) tumors, and CPR (n=12) or non-CPR (n=9) (p=0.670). Pathological response of three HLA-PRO tumors was not evaluated since the patients did not receive surgery. (B) Kaplan-Meier survival curves of progression-free survival (PFS, on the left) and overall survival (OS, on the right) for HLA-proficient (n=14) and HLA-deficient (n=10) patients (p=0.909 and p=0.137). An adjusted p value of<0.05 was considered statistically significant. CPR, complete pathological response; HLA, human leukocyte antigen; HLA-DEF, HLA-deficient; HLA-PRO, HLA-proficient.